{
  "api_version": "1",
  "request": {
    "url": "https://clinicaltrialsfind.com/api/v1/search.json?condition=Antibody-Mediated+Rejection&page=2",
    "query": {
      "condition": "Antibody-Mediated Rejection",
      "page": 2
    },
    "page_size": 10
  },
  "pagination": {
    "page": 2,
    "page_size": 10,
    "total_count": 10,
    "total_pages": 1,
    "next_page_url": null,
    "previous_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?condition=Antibody-Mediated+Rejection&page=1&page_size=10"
  },
  "source": "remote",
  "last_synced_at": "2026-07-24T08:30:35.258Z",
  "attribution": "Data derived from public ClinicalTrials.gov records. The official record at https://clinicaltrials.gov/ remains the source of truth for current availability, contacts, and full study details.",
  "notes": [
    "This endpoint exposes only public summary fields — no participant contact emails, phone numbers, or scraped investigator contact details.",
    "For contact information and full protocol detail, follow each trial's `official_url` to the ClinicalTrials.gov record.",
    "This API is a navigational aid. It does not provide medical advice, eligibility determinations, or compensation guarantees."
  ],
  "trials": [
    {
      "nct_id": "NCT00670774",
      "title": "Dosing Regimen of Eculizumab Added to Conventional Treatment in Positive Cross Match Living Donor Kidney Transplant",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE1",
        "PHASE2"
      ],
      "conditions": [
        "Kidney Transplant"
      ],
      "interventions": [
        {
          "name": "Eculizumab",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Mark Stegall",
      "sponsor_class": "OTHER",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 31,
      "start_date": "2008-03",
      "completion_date": "2017-08",
      "has_results": true,
      "last_update_posted_date": "2018-06-26",
      "last_synced_at": "2026-07-24T08:30:35.258Z",
      "location_count": 1,
      "location_summary": "Rochester, Minnesota",
      "locations": [
        {
          "city": "Rochester",
          "state": "Minnesota"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT00670774"
    },
    {
      "nct_id": "NCT03897205",
      "title": "An Efficacy and Safety Study of Imlifidase in Treatment of Antibody-Mediated Rejection in Kidney Transplant Patients",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE2"
      ],
      "conditions": [
        "Kidney Transplant Rejection"
      ],
      "interventions": [
        {
          "name": "Imlifidase",
          "type": "DRUG"
        },
        {
          "name": "Plasma Exchange",
          "type": "OTHER"
        }
      ],
      "intervention_types": [
        "DRUG",
        "OTHER"
      ],
      "sponsor": "Hansa Biopharma AB",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 30,
      "start_date": "2019-04-30",
      "completion_date": "2022-11-16",
      "has_results": true,
      "last_update_posted_date": "2024-02-28",
      "last_synced_at": "2026-07-24T08:30:35.258Z",
      "location_count": 4,
      "location_summary": "Los Angeles, California • Boston, Massachusetts • Rochester, Minnesota + 1 more",
      "locations": [
        {
          "city": "Los Angeles",
          "state": "California"
        },
        {
          "city": "Boston",
          "state": "Massachusetts"
        },
        {
          "city": "Rochester",
          "state": "Minnesota"
        },
        {
          "city": "New York",
          "state": "New York"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT03897205"
    },
    {
      "nct_id": "NCT00771875",
      "title": "Randomized Trial for Mixed Acute Rejection",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE2"
      ],
      "conditions": [
        "Graft Rejection"
      ],
      "interventions": [
        {
          "name": "Rabbit Antithymocyte Globulin (RATG)",
          "type": "DRUG"
        },
        {
          "name": "Rituximab",
          "type": "DRUG"
        },
        {
          "name": "Bortezomib",
          "type": "DRUG"
        },
        {
          "name": "Acetaminophen",
          "type": "DRUG"
        },
        {
          "name": "Antihistamine",
          "type": "DRUG"
        },
        {
          "name": "Methylprednisolone",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "University of Cincinnati",
      "sponsor_class": "OTHER",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": "65 Years",
        "sex": "ALL",
        "summary": "18 Years to 65 Years"
      },
      "enrollment_count": 30,
      "start_date": "2008-09",
      "completion_date": "2013-03",
      "has_results": true,
      "last_update_posted_date": "2016-01-27",
      "last_synced_at": "2026-07-24T08:30:35.258Z",
      "location_count": 2,
      "location_summary": "Cincinnati, Ohio",
      "locations": [
        {
          "city": "Cincinnati",
          "state": "Ohio"
        },
        {
          "city": "Cincinnati",
          "state": "Ohio"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT00771875"
    },
    {
      "nct_id": "NCT04046549",
      "title": "A Study to Evaluate the Safety and Efficacy of Dual Costimulation Blockade With VIB4920 and Belatacept for Prophylaxis of Allograft Rejection in Adults Receiving a Kidney Transplant",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE2"
      ],
      "conditions": [
        "Allografts",
        "Rejection; Transplant, Kidney",
        "Transplant Rejection",
        "Kidney Transplantation"
      ],
      "interventions": [
        {
          "name": "Belatacept",
          "type": "DRUG"
        },
        {
          "name": "VIB4920",
          "type": "DRUG"
        },
        {
          "name": "Thymoglobulin",
          "type": "DRUG"
        },
        {
          "name": "Methylprednisolone",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Amgen",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": "70 Years",
        "sex": "ALL",
        "summary": "18 Years to 70 Years"
      },
      "enrollment_count": 25,
      "start_date": "2019-10-30",
      "completion_date": "2023-03-22",
      "has_results": true,
      "last_update_posted_date": "2024-12-27",
      "last_synced_at": "2026-07-24T08:30:35.258Z",
      "location_count": 4,
      "location_summary": "Los Angeles, California • San Francisco, California • Durham, North Carolina + 1 more",
      "locations": [
        {
          "city": "Los Angeles",
          "state": "California"
        },
        {
          "city": "San Francisco",
          "state": "California"
        },
        {
          "city": "Durham",
          "state": "North Carolina"
        },
        {
          "city": "Dallas",
          "state": "Texas"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT04046549"
    },
    {
      "nct_id": "NCT07444489",
      "title": "A Study to Learn More About the Long-Term Safety and Effects of Felzartamab Infusions in Adults With Kidney Transplants Who Have Antibody-Mediated Rejection (AMR) or Microvascular Inflammation (MVI) (TRANSCEND/TRANSPIRE LTE)",
      "overall_status": "ENROLLING_BY_INVITATION",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE3"
      ],
      "conditions": [
        "Antibody-mediated Rejection",
        "Microvascular Inflammation"
      ],
      "interventions": [
        {
          "name": "Felzartamab",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Biogen",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": "75 Years",
        "sex": "ALL",
        "summary": "18 Years to 75 Years"
      },
      "enrollment_count": 201,
      "start_date": "2026-04-16",
      "completion_date": "2031-05-28",
      "has_results": false,
      "last_update_posted_date": "2026-06-30",
      "last_synced_at": "2026-07-24T08:30:35.258Z",
      "location_count": 2,
      "location_summary": "Los Angeles, California • West Orange, New Jersey",
      "locations": [
        {
          "city": "Los Angeles",
          "state": "California"
        },
        {
          "city": "West Orange",
          "state": "New Jersey"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT07444489"
    },
    {
      "nct_id": "NCT06918990",
      "title": "Treatment of Antibody-Mediated Rejection (ABMR) With CarBel",
      "overall_status": "RECRUITING",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE1"
      ],
      "conditions": [
        "Kidney Transplant Rejection"
      ],
      "interventions": [
        {
          "name": "Carfilzomib",
          "type": "BIOLOGICAL"
        },
        {
          "name": "Belatacept",
          "type": "BIOLOGICAL"
        }
      ],
      "intervention_types": [
        "BIOLOGICAL"
      ],
      "sponsor": "National Institute of Allergy and Infectious Diseases (NIAID)",
      "sponsor_class": "NIH",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": "75 Years",
        "sex": "ALL",
        "summary": "18 Years to 75 Years"
      },
      "enrollment_count": 25,
      "start_date": "2026-05-29",
      "completion_date": "2027-06-30",
      "has_results": false,
      "last_update_posted_date": "2026-05-26",
      "last_synced_at": "2026-07-24T08:30:35.258Z",
      "location_count": 10,
      "location_summary": "Birmingham, Alabama • Phoenix, Arizona • Los Angeles, California + 7 more",
      "locations": [
        {
          "city": "Birmingham",
          "state": "Alabama"
        },
        {
          "city": "Phoenix",
          "state": "Arizona"
        },
        {
          "city": "Los Angeles",
          "state": "California"
        },
        {
          "city": "Chicago",
          "state": "Illinois"
        },
        {
          "city": "St Louis",
          "state": "Missouri"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT06918990"
    },
    {
      "nct_id": "NCT03380962",
      "title": "Clazakizumab in Highly-HLA Sensitized Patients Awaiting Renal Transplant",
      "overall_status": "ACTIVE_NOT_RECRUITING",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE1",
        "PHASE2"
      ],
      "conditions": [
        "Kidney Failure, Chronic",
        "End-Stage Renal Disease",
        "Transplant Glomerulopathy",
        "Transplant;Failure,Kidney",
        "Kidney Transplant Failure and Rejection",
        "Antibody-mediated Rejection",
        "Kidney Transplant; Complications"
      ],
      "interventions": [
        {
          "name": "Clazakizumab",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Stanley Jordan, MD",
      "sponsor_class": "OTHER",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "15 Years",
        "maximum_age": "75 Years",
        "sex": "ALL",
        "summary": "15 Years to 75 Years"
      },
      "enrollment_count": 20,
      "start_date": "2018-02-27",
      "completion_date": "2025-08-30",
      "has_results": false,
      "last_update_posted_date": "2025-03-24",
      "last_synced_at": "2026-07-24T08:30:35.258Z",
      "location_count": 1,
      "location_summary": "Los Angeles, California",
      "locations": [
        {
          "city": "Los Angeles",
          "state": "California"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT03380962"
    },
    {
      "nct_id": "NCT05004493",
      "title": "Biorepository and Registry for Plasma Exchange Patients",
      "overall_status": "RECRUITING",
      "study_type": "OBSERVATIONAL",
      "phases": [],
      "conditions": [
        "Antibody-mediated Rejection",
        "NMO Spectrum Disorder",
        "TTP",
        "CIDP"
      ],
      "interventions": [],
      "intervention_types": [],
      "sponsor": "Charles M Knudson",
      "sponsor_class": "OTHER",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "12 Years",
        "maximum_age": "99 Years",
        "sex": "ALL",
        "summary": "12 Years to 99 Years"
      },
      "enrollment_count": 200,
      "start_date": "2021-07-28",
      "completion_date": "2040-12-31",
      "has_results": false,
      "last_update_posted_date": "2025-05-20",
      "last_synced_at": "2026-07-24T08:30:35.258Z",
      "location_count": 1,
      "location_summary": "Iowa City, Iowa",
      "locations": [
        {
          "city": "Iowa City",
          "state": "Iowa"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT05004493"
    },
    {
      "nct_id": "NCT06990711",
      "title": "A Phase 1 Clinical Trial of Siltuximab for the Treatment of Antibody-Mediated Rejection After Lung Transplantation",
      "overall_status": "RECRUITING",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE1"
      ],
      "conditions": [
        "Antibody Mediated Rejection of Lung Transplant"
      ],
      "interventions": [
        {
          "name": "Siltuximab",
          "type": "DRUG"
        },
        {
          "name": "Placebo",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Washington University School of Medicine",
      "sponsor_class": "OTHER",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 30,
      "start_date": "2025-11-06",
      "completion_date": "2028-06-30",
      "has_results": false,
      "last_update_posted_date": "2025-12-31",
      "last_synced_at": "2026-07-24T08:30:35.258Z",
      "location_count": 2,
      "location_summary": "St Louis, Missouri • Saint Lake City, Utah",
      "locations": [
        {
          "city": "St Louis",
          "state": "Missouri"
        },
        {
          "city": "Saint Lake City",
          "state": "Utah"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT06990711"
    },
    {
      "nct_id": "NCT05452317",
      "title": "Assess Burden of Disease Among Kidney Transplant Recipients With Chronic Active Antibody Mediated Rejection",
      "overall_status": "COMPLETED",
      "study_type": "OBSERVATIONAL",
      "phases": [],
      "conditions": [
        "Antibody-mediated Rejection in Kidney Transplant"
      ],
      "interventions": [
        {
          "name": "Chronic active AMR group",
          "type": "OTHER"
        },
        {
          "name": "Non-Chronic active AMR group",
          "type": "OTHER"
        }
      ],
      "intervention_types": [
        "OTHER"
      ],
      "sponsor": "CSL Behring",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 52,
      "start_date": "2022-07-14",
      "completion_date": "2023-04-04",
      "has_results": false,
      "last_update_posted_date": "2023-04-13",
      "last_synced_at": "2026-07-24T08:30:35.258Z",
      "location_count": 3,
      "location_summary": "Los Angeles, California • Baltimore, Maryland • St Louis, Missouri",
      "locations": [
        {
          "city": "Los Angeles",
          "state": "California"
        },
        {
          "city": "Baltimore",
          "state": "Maryland"
        },
        {
          "city": "St Louis",
          "state": "Missouri"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT05452317"
    }
  ]
}